^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BNT113

    i
    Associations
    News

    Trials

    Company:
    BioNTech
    Drug class:
    HPV-16 E6 protein inhibitor, HPV-16 E7 protein inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT) (NCT04534205)
    Phase 2
    BioNTech SE
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    01/07/2021
    Primary completion :
    05/01/2028
    Completion :
    05/01/2028
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • BNT113